Search

Your search keyword '"Shinji Urakami"' showing total 224 results
Start Over Author "Shinji Urakami"
224 results on '"Shinji Urakami"'

202. 542: Epigenetic Modifications of RASSF1A Gene Through Chromatin Remodeling in Prostate Cancer

Author

Hideki Enokida, Zhong Chen, Kaveh Vejdani, Ken Kawamoto, Hong Zhao, Shinji Urakami, Deepa Pookot, Toshifumi Kawakami, Shahana Majid, Nobuyuki Kikuno, Rajvir Dahiya, Yuichiro Tanaka, Masayuki Nakagawa, Robert F. Place, Long-Cheng Li, Hiroshi Hirata, and Steven T. Okino

Subjects
Prostate cancer, business.industry, Urology, Cancer research, Medicine, Epigenetics, business, medicine.disease, Gene, Chromatin remodeling
Published
2007

205. 536: Multi-Gene Methylation Analysis For Detection and Staging of Prostate Cancer

Author

Hiroaki Shiina, Rajvir Dahiya, Yuichiro Tanaka, Masayuki Nakagawa, Katsuhisa Mori, Ichiro Kagara, Christopher J. Kane, Long-Cheng Li, Mikio Igawa, Shinji Urakami, Peter R. Carroll, Badrinath R. Konety, Hideki Enokida, and Tatsuya Ogishima

Subjects
Prostate cancer, business.industry, Urology, Methylation analysis, Cancer research, medicine, medicine.disease, business, Multi gene
Published
2006

206. 480: Smoking Influences Aberrant CPG Hypermethylation of Multiple Genes in Human Prostate Cancer

Author

Peter R. Carroll, Yuichiro Tanaka, Ichiro Kagara, Katsuhisa Mori, Masayuki Nakagawa, Hideki Enokida, Hiroaki Shiina, Christopher J. Kane, Shinji Urakami, Badrinath R. Konety, Rajvir Dahiya, Long-Cheng Li, Tatsuya Ogishima, Mikio Igawa, and Masaharu Terashima

Subjects
CpG site, business.industry, Urology, DNA methylation, Cancer research, medicine, Cancer, medicine.disease, business, Gene, Human prostate
Published
2006

208. 606: Wnt Inhibitory Factor-1 Plays an Important Role in Pathogenesis of Bladder Cancer Through the Epigenetic Inactivation

Author

Takashi Tokizane, Nobuyuki Kikuno, Long-Cheng Li, Mikio lgawa, Peter R. Carroll, Christopher J. Kane, Shinji Urakami, Toshifumi Kawakami, Badrinath R. Konety, Hiroaki Shiina, Rajvir Dahiya, Tatsuya Ogishima, and Hideki Enokida

Subjects
Pathogenesis, Bladder cancer, business.industry, Urology, medicine, Wnt signaling pathway, Cancer research, Epigenetics, Inhibitory postsynaptic potential, medicine.disease, business
Published
2006

209. 789: Inactivation of the Human MSH3 Mismatch Repair Gene in Bladder Cancer

Author

Masao Deguchi, Takashi Tokizane, Makoto Fujime, Hideki Enokida, Peter R. Carroll, Z. Laura Tabatabai, Mikio lgawa, Shinji Urakami, Toshifumi Kawakami, Tatsuya Ogishima, Rajvir Dahiya, Christopher J. Kane, Kazukiyo Miura, Leopolda A. Ribeiro-Filho, Kirsten L. Greene, Hiroaki Shiina, Koichi Nakajima, and Nobuhisa Ishii

Subjects
Bladder cancer, MSH3, business.industry, Urology, Cancer research, medicine, DNA mismatch repair, medicine.disease, business, Gene
Published
2005

210. 450: CPG Hypermethylation of MDR1 Gene Contibutes to the Pathogenesis and Progression of Human Prostate Cancer

Author

Z. Laura Tabatabai, Hideki Enokida, Motoshi Kawahara, Shinji Urakami, Toshifumi Kawakami, Peter R. Carroll, Tatsuya Ogishima, Christopher J. Kane, Masayuki Nakagawa, Rajvir Dahiya, Mikio Igawa, Hiroaki Shiina, Long-Cheng Li, and Kirsten L. Greene

Subjects
Pathogenesis, CpG site, business.industry, Urology, DNA methylation, Cancer research, Medicine, Cancer, business, medicine.disease, Mdr1 gene, Human prostate
Published
2005

211. 770: Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Carcinogenesis Through Aberrant Wnt Signaling Activation

Author

Peter R. Carroll, Hiroaki Shiina, Rajvir Dahiya, Z. Laura Tabatabai, Akihiko Okuyama, Tatsuya Ogishima, Takashi Tokizane, Hideki Enokida, Christopher J. Kane, Shinji Urakami, Toshifumi Kawakami, Kirsten L. Greene, Hiroyuki Adachi, and Mikio lgawa

Subjects
Bladder carcinogenesis, business.industry, Urology, Cancer research, Wnt signaling pathway, Medicine, Epigenetics, Inhibitory postsynaptic potential, business
Published
2005

213. 451: Hypomethylation of the Heparanase Promoter in Prostate Cancer and its Positive Association with Early PSA Failure after Radical Prostatectomy

Author

Rajvir Dahiya, Hiroaki Shiina, Shinji Urakami, Toshifumi Kawakami, Hideki Enokida, Z. Laura Tabatabai, Leopoldo A. Ribeiro-Filho, Tatsuya Ogishima, Christopher J. Kane, Alvaro S. Sarkis, Long-Cheng Li, Kazushi Shigeno, Mikio Igawa, Hirofumi Kishi, São Paulo, and Peter R. Carroll

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, business.industry, Prostatectomy, PSA Failure, Urology, medicine.medical_treatment, Internal medicine, Medicine, Heparanase, business, medicine.disease
Published
2005

214. 228: Cytochrome P450 1B1 is Over-Expressed and Regulated by Hypomethylation in Human Prostate Cancer

Author

Rajvir Dahiya, Peter R. Carroll, Z. Laura Tabatabai, Takashi Tokizane, Steven T. Okino, Hideki Enokida, Long-Cheng Li, Christopher J. Kane, Mikio Igawa, Kirsten L. Greene, Tatsuya Ogishima, Akihiko Okuyama, Hiroaki Shiina, Nobuhisa Ishii, Norio Nonomura, Shinji Urakami, and Toshifumi Kawakami

Subjects
business.industry, Urology, CYP1B1, Cancer research, medicine, Cancer, medicine.disease, business, Human prostate
Published
2005

215. 388: Single Nucleotide Polymorphism (SNP) and Splicing Variant in C-Terminal Region of TCF-4 Gene are Related to the Pathogenesis of Prostate Cancer

Author

Hideki Enokida, Peter R. Carroll, Shinji Urakami, Toshifumi Kawakami, Z. Laura Tabatabai, Tatsuya Ogishima, Long-Cheng Li, Hirofumi Kishi, Rajvir Dahiya, Mikio Igawa, Kazushi Shigeno, Alvaro S. Sarkis, Leopolda A. Ribeiro-Filho, Christopher J. Kane, and Hiroaki Shiina

Subjects
Pathogenesis, Genetics, Prostate cancer, Terminal (electronics), business.industry, Urology, RNA splicing, medicine, SNP, Single-nucleotide polymorphism, medicine.disease, business, Gene
Published
2005

216. 446: Adverse Effect of Paclitaxel-Induced Thymidine Phosphorylase Expression on Paclitaxel-Mediated Apoptosis in Human Prostate Cancer Cells

Author

Nobuyuki Kikuno, Kazushi Shigeno, Mikio Igawa, Hirofumi Kishi, Nobuko Moriyama-Gonda, Shinji Urakami, Hiroaki Shiina, and Tatsuaki Yoneda

Subjects
chemistry.chemical_compound, Paclitaxel, chemistry, Apoptosis, business.industry, Urology, Cancer cell, Cancer research, Medicine, Thymidine phosphorylase, business, Adverse effect, Human prostate
Published
2005

217. 392: Promoter Methylation of CYP1A1 Gene in Human Prostate Cancer

Author

Christopher J. Kane, Mikio Igawa, Shinji Urakami, Toshifumi Kawakami, Kazushi Shigeno, Hirofumi Kishi, Alvaro S. Sarkis, Hiroaki Shiina, Leopoldo A. Ribeiro-Filho, Takashi Tokizane, Long-Cheng Li, Rajvir Dahiya, Peter R. Carroll, and Hideki Enokida

Subjects
business.industry, Urology, Promoter methylation, medicine, Cancer research, Cancer, medicine.disease, business, Gene, Human prostate
Published
2005

219. 460 Clinical significance of BCL-2 protein expression in renal cell carcinoma: An immunohistochemical study

Author

Mikio Igawa, H. Shirakawa, Tomoyuki Ishibe, Hiroaki Shiina, and Shinji Urakami

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Programmed cell death, biology, Cell, medicine.disease, Proliferating cell nuclear antigen, medicine.anatomical_structure, Oncology, Apoptosis, Renal cell carcinoma, biology.protein, medicine, Cancer research, Immunohistochemistry, Clinical significance, Antibody
Abstract

The bcl-2 protein has been related to the inhibition of programmed cell death (apoptosis), and its overexpression has been reported in several malignant tumors. In order to elucidate the clinical significance of the bcl-2 protein in renal cell carcinoma, seventy-five renal cell carcinomas were investigated by immunohistochemistry using an anti-human bcl-2 antibody. Moreover, the bcl-2 immunoreactivity was also compared with PCNA and p53 immunoreactivities as well as clinico-pathological findings. In all cases, the bcl-2 immunoreactivity was detectable in not only cancerous areas but also normal renal tubules. The bcl-2 immunoreactivity significantly correlated with M category ( P P 0.01 and P P 0.005), and was proved to be an independent prognostic factor using a multivariate analysis ( P

Published
1995

220. 1138 Clinical significance of proliferating cell nuclear antigen expression in transitional cell carcinoma of the bladder

Author

Shinji Urakami, Mikio Igawa, Hiroaki Shiina, I. lshibe, and H. Shirakawa

Subjects
Cancer Research, Univariate analysis, Pathology, medicine.medical_specialty, Total cystectomy, Disease progression, Biology, medicine.disease, Proliferating cell nuclear antigen, Transitional cell carcinoma, Oncology, biology.protein, medicine, In patient, Clinical significance, Stage (cooking)
Abstract

To elucidate the clinical significance of cellular proliferation in transitional cell carcinoma (TCC) of the bladder, the proliferating cell nuclear antigen (PCNA) expression, pS3 and nm23 immunoreactivities, 2c deviation index (2cDI) and 5c exceeding rate (5cER) were evaluated using an image analyzer. The paraffin embedded materials obtained from 77 patients with non-metastatic untreated TCC of the bladder who received total cystectomy were used in this study. The PCNA expression significantly correlated with the pS3 and nm23 immunoreactivities, 2cDI value and 5cER, respectively. The grade significantly correlated with all of the 5 parameters. Similarly, the stage as well as disease progression significantly correlated with all of the parameters except for the nm23 immunoreactivity. In univariate analysis, the prognostic relevance was noted in grade, stage, PCNA expression, p53 immunoreactivity, 2cDI value and 5cER, whereas not in nm23 immunoreactivity. In multivariate analysis, the PCNA expression, followed by 2cDI value, was the most important variable, however, the p53 immunoreactivity and 5cER were not of independent significance. The results suggest that the tumor growth fraction as assessed by the PCNA expression is an important and independent predictor for survival in patients with TCC of the bladder.

Published
1995

221. Decreased survival of prostate cancer cells in vitro by combined treatment of heat and an antioxidant inhibitor diethyldithiocarbamate (DDC).

Author

Nobuko Moriyama-Gonda, Mikio Igawa, Hiroaki Shiina, Shinji Urakami, and Masaharu Terashima

Subjects
ANTIOXIDANTS, CANCER cells, PROSTATE cancer, CARBAMATES
Abstract

The aim of this study was to examine a modulation of thermotolerance by treatment with combination of heat and the antioxidant inhibitor diethyldithiocarbamate (DDC) of the PC-3 prostate cancer cells. To determine thermotolerance, cells were heated once or twice. Two 1 h exposures at 43 degrees C, with a recovery period in between, revealed better survival/recovery of cells after the second exposure than after the first (fig. 1A + 1B). Additional experiments were performed, heating cells twice (fig. 1B + 1C). First, cells were heated at 43 degrees C for 1 h and, after various recovery times (intervals) at 37 degree C, subsequently reheated at 44 degrees C for 1h. To ensure effective cell killing, efficiency of the combined treatments of 1 mM DDC and heating at 43 or 44 degrees C for 1 h was estimated by measuring cell survival, reactive oxygen species (ROS) generation, superoxide dismutase (SOD) activity and heat shock protein 70 (hsp 70) expression. To obtain a more effective method for subsequent heat exposure, cells were heated twice after a 24 h interval in the presence or absence of 1 mM DDC. ROS generation and SOD activity immediately increased correlating with duration of heating, but their levels gently decreased with time after discontinuation of heating. On the other hand, hsp 70 levels slowly increased, also correlating with duration of heating but continued to increase with time after discontinuation of heating for a certain period. DDC administration coupled with heating at 43 or 44 degrees C significantly decreased cell survival compared to heating alone (p < 0.05). Furthermore, significant decreases in numbers of viable cells were observed for cells after the first heat exposure when combined with DDC as compared to heat alone at 43 and 44 degrees C (p < 0.05). These findings suggest that heat combined with DDC could have potential benefits in the treatment of prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

223. Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer

Author

Shinya Yamamoto, Shinji Urakami, Yasuhisa Fujii, Hitoshi Masuda, Iwao Fukui, Masahiko Oguchi, Junji Yonese, Kazutaka Saito, and Takuyo Kozuka

Subjects
Oncology, Quality of life, Male, medicine.medical_specialty, Intensity-modulated, medicine.medical_treatment, Comorbidity, Article, Body Mass Index, Prostate cancer, Japan, Internal medicine, Sickness Impact Profile, Diabetes Mellitus, Medicine, Health Status Indicators, Humans, Longitudinal Studies, Prospective Studies, Prospective cohort study, Aged, Radiotherapy, business.industry, Public Health, Environmental and Occupational Health, Prostatic Neoplasms, Middle Aged, Prostate-Specific Antigen, medicine.disease, Intensity (physics), Radiation therapy, Prostate-specific antigen, Cerebrovascular Disorders, Logistic Models, Mental Health, Treatment Outcome, Hypertension, Physical therapy, Radiotherapy, Intensity-Modulated, business, Body mass index
Abstract

Purpose The purpose of the study is to assess longitudinal changes in general and disease-specific health-related quality-of-life (HRQOL) indices after intensity-modulated radiotherapy (IMRT) monotherapy for patients with localized prostate cancer (PCA). Methods Between 2006 and 2010, 91 patients with localized PCA underwent IMRT monotherapy and were enrolled into this prospective study. At baseline, and at 3, 6, 12, and 24 months after IMRT, the general and prostate-specific HRQOL were estimated using physical (PCS) and mental component summaries (MCS) calculated using the Medical Outcomes Study 8-Item Short Form Health Survey and Expanded Prostate Cancer Index Composite (EPIC). Results For 2 years, there were no significant changes in EPIC scores in all subscales of urinary domain, hormonal function, and bother. Bowel and sexual function scores decreased after IMRT and did not return to those at baseline (p = 0.006 and

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results